Exchange: NASDAQ·Updated 07:46 PM EDT

ALT News

News
all
press releases
Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care?
Novo's semaglutide expansion into liver disease and other obesity-related conditions can unlock growth, but competition and clinical risks loom.
Zacks
Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care?
Novo's semaglutide expansion into liver disease and other obesity-related conditions can unlock growth, but competition and clinical risks loom.
Zacks
More News
VKTX Stock On Track To Beat LLY, NVO This Month After Obesity Drug Data — Can Viking Win Over Wegovy And Zepbound Users?
Obesity specialist Lou Aronne said switching from a GLP-1 drug to a dual GLP-1/GIP drug could mean greater weight loss.
Stocktwits
VKTX, GPCR, ALT Stocks Rise: Novo Nordisk Signals Bigger M&A As It Chases Over 5 ‘Multi-Blockbusters’
Novo targets over $23 billion in risk-adjusted pipeline sales by 2035, excluding any contribution from future acquisitions.
Stocktwits
Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report?
Altimmune (ALT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger?
ALT's stronger cash position supports pemvidutide's MASH, AUD and ALD programs, but long timelines, funding needs and competition remain risks.
Zacks
Altimmune's Phase III MASH Study Puts 2029 Data in Investor Focus
ALT has moved pemvidutide into Phase III MASH testing, with supportive mid-stage data, regulatory backing and a 2029 readout ahead.
Zacks
Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in Focus
KOD's Zenkuda advances toward regulatory submission as its pipeline gains momentum. Key clinical data is expected later in 2026.
Zacks
ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus
Altimmune posts a narrower Q2 loss. Its $519M in cash supports operations into 2029, while pemvidutide advances across liver and AUD studies.
Zacks
BLTE Stock Rises as FDA Grants Priority Review to Tinlarebant NDA
Belite Bio's tinlarebant wins FDA priority review for Stargardt Disease, with a decision expected in February 2027 after positive phase III data.
Zacks
KOD Begins Late-Stage Study of KSI-501 in Diabetic Macular Edema
Kodiak launches a global phase III study of KSI-501 in DME, testing its dual IL-6 and VEGF approach for durable disease control.
Zacks

Advertisement|Remove ads.